This is part of the Press release from Health Canada:
Health Canada reviewing diabetes drug pioglitazone (Actos) and potential risk of bladder cancer
June 17, 2011
For immediate release
OTTAWA – In light of studies suggesting an increased risk of bladder cancer with the diabetes drug pioglitazone, as well as actions taken by other regulatory agencies, Health Canada is informing healthcare professionals and Canadians that it is undertaking a review of the drug’s status.
Pioglitazone is sold in Canada under the brand name “Actos” in addition to generic forms of the drug. It is used by itself or in combination with other diabetes drugs to control blood sugar levels in diabetic patients, when diet and exercise have failed.
Post-marketing reports of bladder cancer have been reported very rarely with the use of pioglitazone. This information is included in the Canadian Product Monograph. Health Canada has been closely monitoring this potential risk, and has been reviewing all relevant studies on an ongoing basis. We are taking these studies, including their strengths and limitations, into account as we continue to monitor pioglitazone safety.
Actos was a welcomed alternative to the drug Avandia which was restricted due to the increase risk of a Heart Attack.
To read the full press release go to Health Canada
Have a Great Day!!